Health Tip on Drugs for Children Affected with Hepatitis C
The U.S. Food and Drug Administration (FDA) has approved the use of the directly acting agents (DAAs) sofosbuvir (available as Sovaldi) and the combination of ledipasvir and sofosbuvir (available as Harvoni) for the treatment of hepatitis C in children and adolescents between the ages of 12 to 17 years, thereby increasing the possible number of beneficiaries of this new treatment.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer